Table 2.
Treatment and follow-up data.
| Case number | Main sites | Treatment | ALK | PD-L1 | Months after diagnosis | Outcome |
|---|---|---|---|---|---|---|
| 1 | PS | IR + Pred + RT | - | - | 79 | Stable |
| 2 | PS, NP, orbit | IR +Pred + CT | - | + | / | Lost |
| 3 | PS, IF | Pred + CT + RT | - | + | 41 | DOD |
| 4 | PS, orbit | Pred + CT + RT | - | - | 87 | Stable |
| 5 | PS, orbit | IR + Pred + CT | - | + | 12 | Stable |
| 6 | PS, IF | Pred + CT + RT | - | - | 50 | Stable |
| 7 | PS, NP | IR + Pred + RT | + | + | 20 | Stable |
| 8 | PS, orbit | Pred + CT | - | + | 62 | Stable |
| 9 | NC, PS | IR + RT | / | / | / | Lost |
| 10 | NP | Pred + RT | - | + | 22 | Stable |
| 11 | PS, orbit, SB | UK | - | + | / | Lost |
| 12 | PS, SB | CR | - | + | 2 | DOD |
| 13 | Parapharyngeal space | Observation | - | + | 37 | Stable |
CR, Complete resection; CT, chemotherapy; DOD, died of disease; IF, infratemporal fossa; IR, incomplete resection; NC, nasal cavity; NP, nasopharynx; Pred, prednisone; PS, paranasal sinus; RT, radiotherapy; SB: skull base; Stable, alive with disease, but there are various improvements and no disease progression; UK, unknown.